NEW YORK, May 19, 2026, 05:01 (EDT)
- Virax finished Monday at $0.2350, a gain of 53.1%. The stock was indicated up again in premarket trading.
- The move came after a May 15 ownership filing and a sponsored RedChip TV spot over the weekend.
- The company is still a small Nasdaq diagnostics firm. Shares are still trading well under $1.
Virax Biolabs Group shares were higher again in early U.S. premarket trading Tuesday after a big move Monday. The thinly traded diagnostics micro-cap saw a spike in turnover as investors kept looking for a new catalyst.
The Nasdaq stock traded at $0.2751 at 5:00 a.m. EDT, 17.1% higher than where it finished Monday. Shares closed last session at $0.2350, up 53.1%, with about 765.2 million shares crossed. The 52-week range is $0.10 to $1.19, so it’s still priced in penny-stock territory.
Why now: Virax shares moved without any new overnight product approval, earnings, or clinical data update on the company’s investor-relations site. The most recent press release listed was an April 14 shareholder letter. The latest SEC filing was a May 15 ownership filing.
Biotech stocks traded lower, with the SPDR S&P Biotech ETF off roughly 2.3% and the iShares Nasdaq Biotechnology ETF down 1.7% in recent trading. VRAX, though, was still bid up ahead of the bell.
RedChip Companies put out a release saying Virax CEO James Foster is set to appear on “Small Stocks, Big Money,” which runs as a sponsored segment on Bloomberg TV this Saturday, May 16. In its disclosure, RedChip says Virax is a paying client, committed to $12,500 a month for half a year in investor-awareness work and $75,000 for a 10-day national TV ad campaign this month. ACCESS Newswire
Traders got fresh information from a new filing. The May 15 Schedule 13G/A showed Armistice Capital and Steven Boyd control 1,000,239 shares of Virax Biolabs Group Limited, or 4.99% of the class, with shared voting and dispositive power.
Virax is working on T-cell-based tech for tracking immune response in people with post-acute infection syndromes like Long COVID. For now, the company says it is focusing its U.S. launch on a lab-developed test, or LDT, which is used within a single lab. Plans for wider IVD development are on the table for later.
Foster has pitched 2026 as a validation year. In an April letter to shareholders, he wrote, “Our task is to execute.” The company pointed to a PAIS assay-performance data readout, U.S. clinical validation planning with Emory University, and the push to prep for a U.S. LDT route. Virax Biolabs Group Limited
The company announced in March that its UK arm picked up ISO 13485:2016 and ISO 9001:2015 certifications. Foster called it a “meaningful milestone.” The standards cover quality management for design, manufacturing, and risk controls in diagnostics and similar areas. Virax Biolabs Group Limited
Virax pointed to its balance sheet in its bull case. The company said by April 10 all pre-funded warrants tied to the December deal were exercised, putting ordinary shares at 19,923,432. Management had put cash around $6.4 million at March 31, and saw a market value near $2.6 million on April 10. Shares jumped Monday and StockAnalysis showed market cap at about $4.68 million.
Listing risk and dilution are part of the story. Virax said back in July that Nasdaq warned it was below the $1 minimum bid rule. In March, shareholders backed a 1-for-10 to 1-for-15 reverse split and a 2026 plan setting aside 2 million shares for awards.
Virax is going after immune-function testing, setting it apart from rivals who stick to established diagnostics fields. Co-Diagnostics is in PCR-based tech, and Abbott’s deal for Exact Sciences has kept attention on commercial diagnostics that have uptake, not just assets in development.
The rally could flip the other way fast. A sponsored investor-awareness campaign isn’t clinical proof, and Virax’s own warnings admit those forward-looking plans might not happen. If volume drops off, if the PAIS data doesn’t deliver, or the company can’t set up reimbursement, Monday’s pop may just be a quick low-float squeeze, not a real business reset.
Looking to this week, traders are set to track if premarket buying sticks once the bell rings and keep an eye on any new filings or press releases from Virax. Unless there’s a new operational update, trading will stay driven by liquidity, headlines about who’s buying or selling, and bets on the next data release. There’s no sign of new confirmed sales right now.
